PH1001
Research-stage proposed biosimilar candidate referencing trastuzumab
Development code
PH1001
Reference molecule
Trastuzumab
Molecular target
HER2
Therapeutic area
Oncology
Scientific Profile
Development Focus
Development is focused on head-to-head evaluation of primary and higher-order structure, glycosylation, charge and size variants, purity, aggregates, stability, HER2 binding, relevant Fcγ-receptor interactions, antibody-dependent cellular cytotoxicity (ADCC), and HER2-dependent cell-based activity. The reference-product scientific context includes HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal-junction adenocarcinoma; these are not established indications for PH1001.
Proposed Mode of Action
PH1001 is designed to bind the extracellular region of HER2. If the intended comparative functional profile is confirmed, this interaction would be expected to inhibit proliferation in HER2-overexpressing experimental systems and support Fc-mediated ADCC preferentially against HER2-overexpressing target cells. These remain proposed attributes of the candidate.
- PH1001 is a research-stage proposed biosimilar candidate. Biosimilarity, safety, efficacy, approved indications, and interchangeability, where such a designation exists, have not been established for PH1001, and PH1001 has not been approved by any regulatory authority. References to the reference medicine, its mechanism of action, and its authorized indications are provided solely for scientific context and do not imply the same characteristics, clinical profile, or regulatory status for PH1001.